Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

529576 InSolution™ PP2 - Calbiochem

529576
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₁₅H₁₆ClN₅

Products

Catalogue NumberPackaging Qty/Pack
529576-1MGCN Plastic ampoule 1 mg
Description
Catalogue Number529576
Brand Family Calbiochem®
References
ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



Selected Citations
Lee, J., et al. 2009. Cell Stem Cell 5, 76.


Product Information
ATP CompetitiveY
FormClear and colorless liquid
FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
Hill FormulaC₁₅H₁₆ClN₅
Chemical formulaC₁₅H₁₆ClN₅
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationInSolution™ PP2, 172889-27-9, is a 10 mM solution of PP2 (Cat. No. 529573) in DMSO. A potent, reversible, ATP-competitive, inhibitor of the Src family of protein tyrosine kinases.
Biological Information
Primary Targetp56lck
Primary Target IC<sub>50</sub>4 nM, 5 nM, 5 nM, 100 nM, against p56lck, p59fynT, Hck , and Src, respectively; 600 nM against anti-CD3-stimulated tyrosine phosphorylation of human T cells
Purity≥95% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
R PhraseR: 36/37/38

Irritating to eyes, respiratory system and skin.
S PhraseS: 23-26-36

Do not breathe fumes.
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing.
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Irritant
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
529576-1MGCN 07790788051211

Documentation

InSolution™ PP2 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

InSolution™ PP2 - Calbiochem Certificates of Analysis

TitleLot Number
529576

References

Reference overview
Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



Selected Citations
Lee, J., et al. 2009. Cell Stem Cell 5, 76.


Citations

Title
  • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
  • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
  • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
  • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
  • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
  • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
  • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
  • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
  • Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision27-August-2008 RFH
    DescriptionA potent and selective inhibitor of the src family of tyrosine kinases. Its action is similar to PP1. Selectively inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), and Hck (IC50 = 5 nM) compared to other tyrosine kinases, such as EGF-R (IC50 = 480 nM), JAK2 (IC50 >50 µM) or ZAP-70 (IC50 >100 µM). Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC50 = 600 nM).
    FormClear and colorless liquid
    FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
    Intert gas (Yes/No) Packaged under inert gas
    Chemical formulaC₁₅H₁₆ClN₅
    Structure formulaStructure formula
    Purity≥95% by HPLC
    Storage Protect from light
    -20°C
    Do Not Freeze Ok to freeze
    Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
    Toxicity Irritant
    ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



    Selected Citations
    Lee, J., et al. 2009. Cell Stem Cell 5, 76.


    Citation
  • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
  • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
  • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
  • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
  • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
  • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
  • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
  • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.